The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

Haleon's dual-placement strategy for Advil and TUMS at CVS lifted first-quarter sales per store, and talks with Walmart are ...

Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...

Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a ...

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial ...

Janux Therapeutics surged on promising early data and M&A rumors in 2024, but recent clinical updates led to a sharp stock decline. Click for more on JANX.

Christmas, building on 10 successful launches so far in 2026 Stradivarius, Kiko Milano, Bershka, Oliver Bonas, White Stuff, Tommy Hilfiger, Mountain Warehouse and Popeyes among latest investments ...